Copertina

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Zhen Deng, Lincheng Duan, Kai Wang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
di: Alberto Ferrarese, et al.
Pubblicazione: (2025)

Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses
di: Changhu Sun, et al.
Pubblicazione: (2025)

Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting
di: Toni Herta, et al.
Pubblicazione: (2024)

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
di: Shupeng Zhao, et al.
Pubblicazione: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
di: Benedikt Silvester Hofer, et al.
Pubblicazione: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
di: Ewan Forrest, et al.
Pubblicazione: (2025)

Letter: Addressing opioid exposure and associated harms in patients with IBD
di: Christian P. Selinger, et al.
Pubblicazione: (2024)

Letter on ‘Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study’
di: Muhammad Ibrahim Khalil, et al.
Pubblicazione: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Editorial: Addressing Unmet Needs and Socioeconomic Disparity in Patients With Autoimmune Hepatitis
di: Seren Gedallovich, et al.
Pubblicazione: (2024)

Editorial: Hepatitis D Screening—DAS (Delta Virus Awareness and Screening) Approach in Primary Care
di: Noreen Singh, et al.
Pubblicazione: (2025)

Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences
di: Bi‐Yu Gao, et al.
Pubblicazione: (2025)

Letter: Assessing the Durability of Treatment Effects: Long‐Term Outcomes of ESWL and ERCP for Pancreatic Duct Stones in Chronic Pancreatitis
di: Wei‐Zhen Tang, et al.
Pubblicazione: (2024)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks
di: Chun‐Chieh Chen, et al.
Pubblicazione: (2025)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
di: Pinelopi Arvaniti, et al.
Pubblicazione: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
di: Lukas Burghart, et al.
Pubblicazione: (2026)

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?
di: Andrew W. Nguyen, et al.
Pubblicazione: (2026)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
di: Teresa Seum, et al.
Pubblicazione: (2025)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
di: Rui Huang, et al.
Pubblicazione: (2025)

Editorial: HDV Diagnosis Implementation: Gains in Systematic Screening, Gaps in Standardisation
di: Sara Battistella, et al.
Pubblicazione: (2026)

Editorial: Chronic Hepatitis Delta—We Need More Screening to Improve Knowledge on the Natural History
di: J. Ventre, et al.
Pubblicazione: (2025)

Letter: Methodological Flaws and Clinical Gaps—A Critique of TAF / TDF 5‐Year Data in East Asian CHB
di: Zhiyao Shi, et al.
Pubblicazione: (2025)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
di: Merle Claßen, et al.
Pubblicazione: (2024)

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
di: Xingfei Pan, et al.
Pubblicazione: (2025)

Letter on “Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign‐Born: The FOCUS‐HBV Multicentre Cohort”
di: Dong Hyun Kim, et al.
Pubblicazione: (2025)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination
di: Yash Hegde, et al.
Pubblicazione: (2026)

Letter: Methodological Gaps Undermine Conclusions on Electronic Nose Use for Colorectal Cancer Detection—Authors' Reply
di: Milou. L. M. van Riswijk, et al.
Pubblicazione: (2025)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
di: Rui Zhang, et al.
Pubblicazione: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
di: Min Wu, et al.
Pubblicazione: (2024)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
di: Anupam Kumar Singh, et al.
Pubblicazione: (2026)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
di: Vibeke Strande, et al.
Pubblicazione: (2024)

Letter on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment”
di: Yan Liu, et al.
Pubblicazione: (2025)

Surviving Hepatitis C—Understanding Death and Survival Beyond Cure
di: Paul J. Clark, et al.
Pubblicazione: (2025)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
di: YaoYao Dai, et al.
Pubblicazione: (2025)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass
di: Catherine Jia Lin Tian, et al.
Pubblicazione: (2024)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
di: Maria Buti
Pubblicazione: (2025)